Cargando…

LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease

Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are one of the most frequent genetic causes of both familial and sporadic Parkinson’s disease (PD). Mounting evidence has demonstrated pathological similarities between LRRK2-associated PD (LRRK2-PD) and sporadic PD, suggesting that LRRK2 is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Eunice Eun Seo, Ho, Philip Wing-Lok, Liu, Hui-Fang, Pang, Shirley Yin-Yu, Leung, Chi-Ting, Malki, Yasine, Choi, Zoe Yuen-Kiu, Ramsden, David Boyer, Ho, Shu-Leong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842874/ https://www.ncbi.nlm.nih.gov/pubmed/35152914 http://dx.doi.org/10.1186/s40035-022-00285-2

Ejemplares similares

In vivo overexpression of synaptogyrin‐3 promotes striatal synaptic dopamine uptake in LRRK2(R1441G) mutant mouse model of Parkinson's disease
por: Ho, Philip Wing‐Lok, et al.
Publicado: (2023)

LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease
por: Pang, Shirley Yin-Yu, et al.
Publicado: (2022)

Long-term inhibition of mutant LRRK2 hyper-kinase activity reduced mouse brain α-synuclein oligomers without adverse effects
por: Ho, Philip Wing-Lok, et al.
Publicado: (2022)

Aberrant mitochondrial morphology and function associated with impaired mitophagy and DNM1L-MAPK/ERK signaling are found in aged mutant Parkinsonian LRRK2(R1441G) mice
por: Liu, Huifang, et al.
Publicado: (2020)

Transcriptional Regulation of the Synaptic Vesicle Protein Synaptogyrin-3 (SYNGR3) Gene: The Effects of NURR1 on Its Expression
por: Li, Lingfei, et al.
Publicado: (2022)

Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease
por: Liu, Hui-Fang, et al.
Publicado: (2017)

Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA)
por: Ho, Philip Wing-Lok, et al.
Publicado: (2019)

The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease
por: Pang, Shirley Yin-Yu, et al.
Publicado: (2019)

LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity
por: Liu, Hui-Fang, et al.
Publicado: (2014)

LRRK2 in Transcription and Translation Regulation: Relevance for Parkinson’s Disease
por: Dorval, Véronique, et al.
Publicado: (2012)

The LRRK2–macroautophagy axis and its relevance to Parkinson's disease
por: Manzoni, Claudia
Publicado: (2017)

Pharmacological rescue of impaired mitophagy in Parkinson’s disease-related LRRK2 G2019S knock-in mice
por: Singh, Francois, et al.
Publicado: (2021)

Antioxidants inhibit neuronal toxicity in Parkinson's disease‐linked LRRK2
por: Angeles, Dario C., et al.
Publicado: (2016)

Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse Brains
por: Kim, Jungwoo Wren, et al.
Publicado: (2021)

Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice
por: Beccano-Kelly, Dayne A., et al.
Publicado: (2014)

Commentary on “Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice”
por: Popugaeva, Elena, et al.
Publicado: (2014)

Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous Lrrk2 mutations and ameliorated by Lrrk2 genetic knock-out
por: MacIsaac, Sarah, et al.
Publicado: (2020)

Mitochondrial Uncoupling Protein-2 (UCP2) Mediates Leptin Protection Against MPP(+) Toxicity in Neuronal Cells
por: Ho, Philip Wing-Lok, et al.
Publicado: (2009)

Induced pluripotent stem cell‐based modeling of mutant LRRK2‐associated Parkinson's disease
por: Weykopf, Beatrice, et al.
Publicado: (2019)

Assessment of Cellular Estrogenic Activity Based on Estrogen Receptor-Mediated Reduction of Soluble-Form Catechol-O-Methyltransferase (COMT) Expression in an ELISA-Based System
por: Ho, Philip Wing-Lok, et al.
Publicado: (2013)

Models for LRRK2-Linked Parkinsonism
por: Li, Tianxia, et al.
Publicado: (2011)

The role of the LRRK2 gene in Parkinsonism
por: Li, Jie-Qiong, et al.
Publicado: (2014)

LRRK2 and Proteostasis in Parkinson’s Disease
por: Pérez-Carrión, María Dolores, et al.
Publicado: (2022)

Targeting LRRK2 in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

LRRK2 A419V Is Not Associated with Parkinson's Disease in Different Chinese Populations
por: Wu, Yih Ru, et al.
Publicado: (2012)

Reply to: Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice through Activating TNF‐α Pathway
por: Lin, Chin‐Hsien, et al.
Publicado: (2022)

Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors
por: Ito, Genta, et al.
Publicado: (2016)

Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson’s disease
por: Kozina, Elena, et al.
Publicado: (2022)

Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease
por: Lee, Byoung Dae, et al.
Publicado: (2010)

Endosomal traffic and glutamate synapse activity are increased in VPS35 D620N mutant knock-in mouse neurons, and resistant to LRRK2 kinase inhibition
por: Kadgien, Chelsie A., et al.
Publicado: (2021)

Rare variants in LRRK1 and Parkinson's disease
por: Schulte, Eva C., et al.
Publicado: (2013)

The Role of LRRK2 in Neurodegeneration of Parkinson Disease
por: Rui, Qin, et al.
Publicado: (2018)

LRRK2 and the Endolysosomal System in Parkinson’s Disease
por: Erb, Madalynn L., et al.
Publicado: (2020)

LRRK2 at the Crossroad of Aging and Parkinson’s Disease
por: Hur, Eun-Mi, et al.
Publicado: (2021)

Pathological Functions of LRRK2 in Parkinson’s Disease
por: Jeong, Ga Ram, et al.
Publicado: (2020)

Modeling Parkinson’s disease in LRRK2 rodents
por: Domenicale, Chiara, et al.
Publicado: (2023)

Parkinson’s Disease-Associated Mutant LRRK2-Mediated Inhibition of miRNA Activity is Antagonized by TRIM32
por: Gonzalez-Cano, Laura, et al.
Publicado: (2017)

Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase
por: Lis, Pawel, et al.
Publicado: (2018)

Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice
por: Domenicale, Chiara, et al.
Publicado: (2022)

Surfactant Secretion in LRRK2 Knock-Out Rats: Changes in Lamellar Body Morphology and Rate of Exocytosis
por: Miklavc, Pika, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v30225fb596f4962cif9ksb2hc